04:42 PM EDT, 07/14/2025 (MT Newswires) -- Ascendis Pharma ( ASND ) said late Monday its phase 3 trial of TransCon PTH, or palopegteriparatide, showed sustained efficacy in adults with hypoparathyroidism at week 156.

The three-year trial data revealed clinically meaningful improvement in skeletal dynamics, kidney function, hypoparathyroidism-related symptoms, and quality of life, according to a statement.

The treatment was well tolerated without any new safety signals, and adverse events were mostly mild to moderate, the company said.

Shares were up 1.9% during after-hours trading.